- Pricing problems for diabetes treatments
- Controversy over Regeneron’s copay support
- Massachusetts concedes that coupons help some patients (but accumulators hurt)
- A 2020 update to my all-time favorite chart
P.S. Join the more than 9,700 followers of my curated links published on @DrugChannels on Twitter. My recent tweets have highlighted: VC’s pharmacy love, physicians’ biosimilar concerns, drug trend in workers’ comp, copay accumulator news, the outlook for insurance costs, remdesivir pricing, Philly pharmacies, how paid parking boosts telemedicine, and more.